Immunotherapy in lung cancer
Open Access
- 1 August 1998
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 78 (3) , 282-288
- https://doi.org/10.1038/bjc.1998.486
Abstract
More research and new treatment options are needed in all stages of lung cancer. To this end immunotherapy needs a revival in view of recent improved technologies and greater understanding of the underlying biology. In this review we discuss mechanisms of tumour immunotherapy, non-specific, specific and adoptive, with particular reference to a direct therapeutic action on all subtypes of lung cancer.Keywords
This publication has 68 references indexed in Scilit:
- The Th1/Th2 paradigmImmunology Today, 1997
- Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-αl and interferon-α2aPublished by Elsevier ,1995
- Constitutive secretion of bioactive transforming growth factor β1 by small cell lung cancer cell linesEuropean Journal Of Cancer, 1994
- Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: Preliminary resultsEuropean Journal Of Cancer, 1993
- Cancer vaccinesImmunology Today, 1993
- Natural interferon alfa as maintenance therapy for small cell lung cancerEuropean Journal Of Cancer, 1992
- Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with non-small-cell lung cancer: Toxicity and immunomodulatory effectsCancer Immunology, Immunotherapy, 1991
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986
- Levamisole as an adjuvant to chemotherapy in extensive bronchogenic carcinoma. A veterans administration lung cancer group studyCancer, 1982